STRATA Skin Sciences, Inc. has established a unique market niche through its FDA-cleared XTRAC excimer laser systems targeting dermatologic disorders with a recurring revenue model that aligns with physician usage. Although operating losses have shown improvement in 2025, the company continues to face persistent liquidity constraints and legal challenges, including significant sales tax assessments and healthcare fraud scrutiny. Trade policy shifts add another layer of uncertainty for cost and demand dynamics. Moving forward, cash flow management and regulatory compliance will be critical as STRATA seeks to convert clinical validation into stronger commercial momentum amid competitive pressures.